<DOC>
	<DOCNO>NCT00202995</DOCNO>
	<brief_summary>Randomized study design look difference relapse rate patient remain current interferon medication switch Copaxone®</brief_summary>
	<brief_title>Randomized Study Designed Look Disease Progression Using 2 Currently FDA Approved Drugs Treatment RRMS</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>1 . Patients must diagnosis clinically definite MS relapse disease course determine Poser criterion 2 . Patients must high dose interferon therapy ( Betaseron® 250 µg Rebif® 44 µg ) least 1 year prior study entry 3 . Patients must experience least one document relapse past year prior screen . Pseudorelapses must rule . A gadolinium enhance lesion require . 4 . Patients must ambulatory , Kurtzke EDSS score 05 inclusive 5 . Patients must age 18 50 year inclusive 6 . Women childbearing potential must practice acceptable method birth control . Acceptable method include oral contraceptive , contraceptive patch , longacting injectable contraceptive , doublebarrier method ( condom IUD spermicide ) , partner 's vasectomy 7 . Patients must relapsefree corticosteroid ( IV oral ) least 30 day prior screen visit 8 . Patients must relapsefree corticosteroid screen baseline visit 9 . Patients must willing able give write informed consent 1 . Use experimental investigational drug , and/or participation investigational drug study within 6 month prior study entry 2 . Previous treatment glatiramer acetate ( injectable ) 3 . Previous treatment immunomodulators ( except IFNβ ) , immunosuppressive agent , IVIG , plasma exchange 6 month prior screen ; previous treatment cladribine past 2 year 4 . Previous total body irradiation total lymphoid irradiation 5 . Chronic corticosteroid ( IV , IM , and/or PO ) treatment ( 30 consecutive day ) 6 month prior study entry 6 . Pregnancy breastfeed 7 . Lifethreatening clinically significant disease 8 . Any condition investigator feel may interfere participation study , include alcohol and/or drug abuse 9 . A known sensitivity gadolinium ( gadolinium acid ) 10 . A known history sensitivity mannitol 11 . Inability successfully undergo MRI scanning</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>